CareDx, Inc. (CDNA) · page 4 of 29
The slide argues that AlloSure has high false negative rates for subclinical rejection and that its commercial success is driven by regulatory loopholes rather than clinical utility.
Research note · research-note · diagnose_problem · overcrowded density
Slide locked Sign in to view
Slide schematic 8/8
paragraph 6/6 source-note 2/2
Components 8
paragraph paragraph paragraph paragraph paragraph paragraph source-note source-note
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.